|

Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

RECRUITINGSponsored by Wake Forest University Health Sciences
Actively Recruiting
SponsorWake Forest University Health Sciences
Started2019-05-16
Est. completion2027-02
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03890614

Summary

The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care.
* The ability to understand and willingness to sign an IRB approved informed consent document.

Conditions2

CancerHematologic Malignancy

Locations1 site

Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.